FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2338146880> ?p ?o ?g. }

• W2338146880 endingPage "2450" @default.
• W2338146880 startingPage "2444" @default.
• W2338146880 abstract "Abstract In two previous studies, we observed that recombinant human interleukin- 3 (IL-3) induced an increase in marrow burst-forming unit-erythroid- derived colonies in vitro in some patients with Diamond-Blackfan anemia (DBA). To determine whether a similar erythropoietic response could be induced in vivo, we treated 13 patients with DBA (aged 4 to 19 years) with two preparations of IL-3. All patients had absent absolute reticulocyte counts and markedly reduced to absent recognizable bone marrow erythroid elements; patients with circulating reticulocytes in the previous 12 months were excluded from study. All patients except 1 had failed steroid therapy and had been transfusion-dependent since infancy; 1 patient was maintained on high-dose prednisone at the time of enrollment. On the first arm of the study, IL-3 (Immunex Corp, Seattle, WA) was administered subcutaneously using a dose escalation regimen of 125 to 500 micrograms/m2/day in divided dosage at 12-hour intervals, coadministered with 1.5 mg/kg/d of oral ferrous sulphate. Of the 13 patients that entered the trial, 4 stopped prematurely because of adverse side effects. In the other 9 evaluable cases, reticulocytes increased transiently in 1 patient from 0 to 65 x 10(9)/L after 35 days of IL-3 therapy at 250 micrograms/m2, but transfusion dependency persisted. One transient peak in absolute reticulocyte count was noted in 6 other patients, but no erythroid response was observed after completion of a full course of IL-3. Oral prednisone at 0.5 mg/kg/d was then coadministered with IL-3 at 500 micrograms/m2 to 5 of the patients without effect, and treatment was stopped. In 2 patients, a second preparation of IL-3 (Sandoz Canada Inc, Dorval, Quebec, Canada) was initiated in a dose escalation regimen of 2.5 to 10 micrograms/kg and was coadministered with ferrous sulphate. No erythroid response was observed in either patient, and in one of the two, alternate-day subcutaneous recombinant erythropoietin at 300 U/kg was administered for 3 weeks in combination with daily IL-3 at 10 micrograms/kg, but no increased erythropoiesis was seen. Significant increases in white blood cell and eosinophil counts during administration of both preparations of IL-3 were observed in all patients. These data show that the response of DBA patients to IL-3 in vivo is heterogeneous and cannot be predicted from in vitro studies. The absence of a corrective effect of IL-3 in these patients with DBA indicates that a deficiency of the cytokine is not central in the pathogenesis of the disorder." @default.
• W2338146880 created "2016-06-24" @default.
• W2338146880 creator A5024238908 @default.
• W2338146880 creator A5059528446 @default.
• W2338146880 creator A5063823763 @default.
• W2338146880 creator A5067753758 @default.
• W2338146880 creator A5080739769 @default.
• W2338146880 creator A5090231970 @default.
• W2338146880 date "1994-05-01" @default.
• W2338146880 modified "2023-09-29" @default.
• W2338146880 title "Failure of recombinant human interleukin-3 therapy to induce erythropoiesis in patients with refractory Diamond-Blackfan anemia [see comments]" @default.
• W2338146880 cites W1484947470 @default.
• W2338146880 cites W1505622392 @default.
• W2338146880 cites W156384325 @default.
• W2338146880 cites W1994455531 @default.
• W2338146880 cites W2063436204 @default.
• W2338146880 cites W2112811492 @default.
• W2338146880 cites W2140922568 @default.
• W2338146880 cites W2161315957 @default.
• W2338146880 cites W2181457518 @default.
• W2338146880 cites W2272486893 @default.
• W2338146880 cites W232308607 @default.
• W2338146880 cites W2338755716 @default.
• W2338146880 cites W2395907880 @default.
• W2338146880 cites W2396651646 @default.
• W2338146880 cites W2403471651 @default.
• W2338146880 cites W2409992445 @default.
• W2338146880 cites W2410903228 @default.
• W2338146880 cites W26214538 @default.
• W2338146880 cites W27594414 @default.
• W2338146880 cites W43111950 @default.
• W2338146880 doi "https://doi.org/10.1182/blood.v83.9.2444.2444" @default.
• W2338146880 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/8167334" @default.
• W2338146880 hasPublicationYear "1994" @default.
• W2338146880 type Work @default.
• W2338146880 sameAs 2338146880 @default.
• W2338146880 citedByCount "21" @default.
• W2338146880 countsByYear W23381468802012 @default.
• W2338146880 countsByYear W23381468802013 @default.
• W2338146880 countsByYear W23381468802018 @default.
• W2338146880 countsByYear W23381468802020 @default.
• W2338146880 crossrefType "journal-article" @default.
• W2338146880 hasAuthorship W2338146880A5024238908 @default.
• W2338146880 hasAuthorship W2338146880A5059528446 @default.
• W2338146880 hasAuthorship W2338146880A5063823763 @default.
• W2338146880 hasAuthorship W2338146880A5067753758 @default.
• W2338146880 hasAuthorship W2338146880A5080739769 @default.
• W2338146880 hasAuthorship W2338146880A5090231970 @default.
• W2338146880 hasBestOaLocation W23381468801 @default.
• W2338146880 hasConcept C104317684 @default.
• W2338146880 hasConcept C105580179 @default.
• W2338146880 hasConcept C126322002 @default.
• W2338146880 hasConcept C141071460 @default.
• W2338146880 hasConcept C197934379 @default.
• W2338146880 hasConcept C203014093 @default.
• W2338146880 hasConcept C2778248108 @default.
• W2338146880 hasConcept C2778403015 @default.
• W2338146880 hasConcept C2778720950 @default.
• W2338146880 hasConcept C2778997081 @default.
• W2338146880 hasConcept C2779703530 @default.
• W2338146880 hasConcept C2780007613 @default.
• W2338146880 hasConcept C2781413609 @default.
• W2338146880 hasConcept C55493867 @default.
• W2338146880 hasConcept C67705224 @default.
• W2338146880 hasConcept C71924100 @default.
• W2338146880 hasConcept C86803240 @default.
• W2338146880 hasConcept C88478588 @default.
• W2338146880 hasConcept C90924648 @default.
• W2338146880 hasConceptScore W2338146880C104317684 @default.
• W2338146880 hasConceptScore W2338146880C105580179 @default.
• W2338146880 hasConceptScore W2338146880C126322002 @default.
• W2338146880 hasConceptScore W2338146880C141071460 @default.
• W2338146880 hasConceptScore W2338146880C197934379 @default.
• W2338146880 hasConceptScore W2338146880C203014093 @default.
• W2338146880 hasConceptScore W2338146880C2778248108 @default.
• W2338146880 hasConceptScore W2338146880C2778403015 @default.
• W2338146880 hasConceptScore W2338146880C2778720950 @default.
• W2338146880 hasConceptScore W2338146880C2778997081 @default.
• W2338146880 hasConceptScore W2338146880C2779703530 @default.
• W2338146880 hasConceptScore W2338146880C2780007613 @default.
• W2338146880 hasConceptScore W2338146880C2781413609 @default.
• W2338146880 hasConceptScore W2338146880C55493867 @default.
• W2338146880 hasConceptScore W2338146880C67705224 @default.
• W2338146880 hasConceptScore W2338146880C71924100 @default.
• W2338146880 hasConceptScore W2338146880C86803240 @default.
• W2338146880 hasConceptScore W2338146880C88478588 @default.
• W2338146880 hasConceptScore W2338146880C90924648 @default.
• W2338146880 hasIssue "9" @default.
• W2338146880 hasLocation W23381468801 @default.
• W2338146880 hasOpenAccess W2338146880 @default.
• W2338146880 hasPrimaryLocation W23381468801 @default.
• W2338146880 hasRelatedWork W117041192 @default.
• W2338146880 hasRelatedWork W1758020640 @default.
• W2338146880 hasRelatedWork W1986660940 @default.
• W2338146880 hasRelatedWork W1987589890 @default.
• W2338146880 hasRelatedWork W2044546219 @default.
• W2338146880 hasRelatedWork W2410011835 @default.
• W2338146880 hasRelatedWork W2415313039 @default.

• next